Shots:

• In accordance with the expiration of the effective period of the co-marketing agreement- the companies will terminate their co-marketing agreement for Clexane SC Kit 2000 IU on Dec 31- 2019
• In Jan’2008- Sanofi got manufacturing and marketing approval for Clexane SC Kit 2000 IU while Kaken initiated marketing and information service activities in Jul’2010 under the co-marketing agreement between the two companies
• Clexane is an anticoagulant therapy indicated to prevent venous thromboembolism. From Jan 01- 2020 Sanofi will start marketing and information service activities for Clexane on its own

Click here to­ read full press release/ article | Ref: Kaken | Image: Amcham